Recombinant Anti-non-muscle Myosin IIA antibody [EPR8965] (ab138498)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR8965] to non-muscle Myosin IIA
- Suitable for: Flow Cyt (Intra), WB, IHC-P, ICC/IF
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-non-muscle Myosin IIA antibody [EPR8965]
See all non-muscle Myosin IIA primary antibodies -
Description
Rabbit monoclonal [EPR8965] to non-muscle Myosin IIA -
Host species
Rabbit -
Tested applications
Suitable for: Flow Cyt (Intra), WB, IHC-P, ICC/IFmore details
Unsuitable for: IP -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide within Human non-muscle Myosin IIA aa 1900-2000. The exact sequence is proprietary.
-
Positive control
- HeLa, HT-29, Jurkat, HUVEC, Human fetal kidney, and A431 lysates, Human kidney and Human lung tissues, A431 and HeLa cells
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
EPR8965 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
- Alexa Fluor® 488 Anti-non-muscle Myosin IIA antibody [EPR8965] (ab204675)
- Alexa Fluor® 647 Anti-non-muscle Myosin IIA antibody [EPR8965] (ab204676)
- HRP Anti-non-muscle Myosin IIA antibody [EPR8965] (ab205470)
- PE Anti-non-muscle Myosin IIA antibody [EPR8965] (ab211837)
- Anti-non-muscle Myosin IIA antibody [EPR8965] - BSA and Azide free (ab236073)
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab138498 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt (Intra) |
1/10 - 1/100.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
|
WB | (1) |
1/1000 - 1/10000. Detects a band of approximately 230 kDa (predicted molecular weight: 227 kDa).
|
IHC-P |
1/250 - 1/500. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
|
ICC/IF |
1/250 - 1/500.
|
Notes |
---|
Flow Cyt (Intra)
1/10 - 1/100. ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
WB
1/1000 - 1/10000. Detects a band of approximately 230 kDa (predicted molecular weight: 227 kDa). |
IHC-P
1/250 - 1/500. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
ICC/IF
1/250 - 1/500. |
Target
-
Function
Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. -
Tissue specificity
In the kidney, expressed in the glomeruli. Also expressed in leukocytes. -
Involvement in disease
Defects in MYH9 are the cause of May-Hegglin anomaly (MHA) [MIM:155100]. MHA is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukokyte inclusions appearing as highly parallel paracrystalline bodies.
Defects in MYH9 are the cause of Sebastian syndrome (SBS) [MIM:605249]. SBS is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukocyte inclusions that are smaller and less organized than in May-Hegglin anomaly.
Defects in MYH9 are the cause of Fechtner syndrome (FTNS) [MIM:153640]. FTNS is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukocyte inclusions that are small and poorly organized. Additionally, FTNS is distinguished by Alport-like clinical features of sensorineural deafness, cataracts and nephritis.
Defects in MYH9 are the cause of Alport syndrome with macrothrombocytopenia (APSM) [MIM:153650]. APSM is an autosomal dominant disorder characterized by the association of ocular lesions, sensorineural hearing loss and nephritis (Alport syndrome) with platelet defects.
Defects in MYH9 are the cause of Epstein syndrome (EPS) [MIM:153650]. EPS is an autosomal dominant disorder characterized by the association of macrothrombocytopathy, sensorineural hearing loss and nephritis.
Defects in MYH9 are the cause of deafness autosomal dominant type 17 (DFNA17) [MIM:603622]. DFNA17 is a form of sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA17 is characterized by progressive hearing impairment and cochleosaccular degeneration.
Defects in MYH9 are the cause of macrothrombocytopenia with progressive sensorineural deafness (MPSD) [MIM:600208]. MPSD is an autosomal dominant disorder characterized by the association of macrothrombocytopathy and progressive sensorineural hearing loss without renal dysfunction.
Note=Subjects with mutations in the motor domain of MYH9 present with severe thrombocytopenia and develop nephritis and deafness before the age of 40 years, while those with mutations in the tail domain have a much lower risk of noncongenital complications and significantly higher platelet counts. The clinical course of patients with mutations in the four most frequently affected residues of MYH9 (responsible for 70% of MYH9-related cases) were evaluated. Mutations at residue 1933 do not induce kidney damage or cataracts and cause deafness only in the elderly, those in position 702 result in severe thrombocytopenia and produce nephritis and deafness at a juvenile age, while alterations at residue 1424 or 1841 result in intermediate clinical pictures.
Note=Genetic variations in MYH9 are associated with non-diabetic end stage renal disease (ESRD). -
Sequence similarities
Contains 1 IQ domain.
Contains 1 myosin head-like domain. -
Domain
The rodlike tail sequence is highly repetitive, showing cycles of a 28-residue repeat pattern composed of 4 heptapeptides, characteristic for alpha-helical coiled coils. -
Post-translational
modificationsISGylated. - Information by UniProt
-
Database links
- Entrez Gene: 4627 Human
- Omim: 160775 Human
- SwissProt: P35579 Human
- Unigene: 474751 Human
-
Alternative names
- BDPLT 6 antibody
- BDPLT6 antibody
- Cellular myosin heavy chain antibody
see all
Images
-
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: non-muscle Myosin IIA knockout HAP1 cell lysate (20 µg)
Lane 3: HeLa cell lysate (20 µg)
Lane 4: HEK293 cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab138498 observed at 230 kDa. Red - loading control, ab18058, observed at 124 kDa.
ab138498 was shown to specifically react with non-muscle Myosin IIA in wild-type HAP1 cells. No band was observed when non-muscle Myosin IIA knockout samples were examined. Wild-type and non-muscle Myosin IIA knockout samples were subjected to SDS-PAGE. ab138498 at a dilution of 1/1000 and ab18058 (loading control to Vinculin) at a dilution of 1/10,000 were incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging. -
Immunohistochemical analysis of paraffin embedded Human kidney tissue labelling non-muscle Myosin IIA with ab138498 antibody at a dilution of 1/250.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
Intracellular Flow Cytometry analysis of HeLa (Human cervix adenocarcinoma epithelial cell) cells labeling non-muscle Myosin IIA with purified ab138498 at 1/20 dilution (10 µg/mL) (Red). Cells were fixed with 4% Paraformaldehyde and permeabilised with 90% Methanol. A Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) secondary antibody was used at 1/2000. Isotype control - Rabbit monoclonal IgG (Black). Unlabeled control - Cells without incubation with primary antibody and secondary antibody (Blue).
-
Immunofluorescent analysis of A431 cells labelling non-muscle Myosin IIA with ab138498 at 1/250 dilution.
-
All lanes : Anti-non-muscle Myosin IIA antibody [EPR8965] (ab138498) at 1/1000 dilution
Lane 1 : HeLa lysate
Lane 2 : HT-29 lysate
Lane 3 : Jurkat lysate
Lane 4 : HUVEC lysate
Lane 5 : Human fetal kidney lysate
Lane 6 : A431 lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 227 kDa
Observed band size: 230 kDa why is the actual band size different from the predicted? -
Immunohistochemical analysis of paraffin embedded Human lung tissue labelling non-muscle Myosin IIA with ab138498 antibody at a dilution of 1/250.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
Immunofluorescent analysis of HeLa cells labelling non-muscle Myosin IIA with ab138498 at 1/250 dilution.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (8)
ab138498 has been referenced in 8 publications.
- Ke W et al. The distinct roles of myosin IIA and IIB under compression stress in nucleus pulposus cells. Cell Prolif 54:e12987 (2021). PubMed: 33415745
- Yang S et al. Long noncoding RNA ERLR mediates epithelial-mesenchymal transition of retinal pigment epithelial cells and promotes experimental proliferative vitreoretinopathy. Cell Death Differ 28:2351-2366 (2021). PubMed: 33664479
- Sun X et al. MYH9 Inhibition Suppresses TGF-ß1-Stimulated Lung Fibroblast-to-Myofibroblast Differentiation. Front Pharmacol 11:573524 (2020). PubMed: 33519439
- Harms RZ et al. Anti-human Interleukin(IL)-4 Clone 8D4-8 Cross-Reacts With Myosin-9 Associated With Apoptotic Cells and Should Not Be Used for Flow Cytometry Applications Querying IL-4 Expression. Front Cell Dev Biol 7:46 (2019). PubMed: 31024909
- Cheng L et al. Aberrant expression of MYH9 and E-cadherin in esophageal squamous cell carcinoma and their relationship to vasculogenic mimicry. Int J Clin Exp Pathol 12:2205-2214 (2019). PubMed: 31934043
- Kay C et al. A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease. Am J Hum Genet 105:1112-1125 (2019). PubMed: 31708117
- Su X et al. Embryonic lethality in mice lacking Trim59 due to impaired gastrulation development. Cell Death Dis 9:302 (2018). PubMed: 29467473
- Wang Z et al. IFT88 influences chondrocyte actin organization and biomechanics. Osteoarthritis Cartilage 24:544-54 (2016). PubMed: 26493329